液体活检在神经胶质母细胞瘤诊断中的应用进展  

Progress in the application of liquid biopsy in the diagnosis of glioblastoma

作　　者：袁铠锟 徐立博 李青松[1,2] YUAN Kaikun;XU Libo;LI Qingsong(The Second Clinical Hospital Affiliated to Harbin Medical University,Heilongjiang Harbin 150086,China;Translational Medicine Research and Cooperation Center of Northern China,Heilongjiang Academy of Medical Sciences,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属第二医院,黑龙江哈尔滨150086 [2]黑龙江省医学科学院北方转化医学研究合作中心,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2023年第7期1375-1378,共4页Journal of Modern Oncology

摘　　要：胶质母细胞瘤(glioblastoma,GBM)是侵袭性极高、预后极差的中枢神经系统肿瘤。目前对于GBM的诊断主要依靠于影像学和组织活检。精准医学时代,液体活检这种相对无创的新兴检测手段已在诸多实体瘤中取得了显著的进展。与传统检测技术相比,液体活检弥补了传统组织活检有创和无法反复取样的局限。本文将针对液体活检循环肿瘤标志物如循环肿瘤DNA、microRNA、循环肿瘤细胞和外泌体在GBM中的应用进展进行综述。Glioblastoma(GBM) is a central nervous system tumor with extremely aggressive and poor prognosis.At present,the diagnosis of GBM mainly relies on imaging and tissue biopsy.In the era of precision medicine,liquid biopsy,a relatively non-invasive new detection method,has made significant progress in many solid tumors.Compared with traditional laboratory technology,liquid biopsy makes up for the limitations of traditional tissue biopsy that are invasive and cannot be sampled repeatedly.This article will review the application progress of circulating tumor markers such as circulating tumor DNA,microRNA,circulating tumor cells and exosomes in GBM for liquid biopsy.

关 键 词：胶质母细胞瘤 循环分子标志物 液体活检 

分 类 号：R739.4[医药卫生—肿瘤]